Case report of a 13-year-old female with trauma secondary to a fall from a golf cart, found to have intraparenchymal & subarachnoid hemorrhages with transverse sinus thrombosis - Donato UMJ, Donato S, Galligan A.
Cerebral venous sinus thrombosis (CVST) is the occlusion of cerebral veins of the brain secondary to blood clot formation. These can result in increased intracranial pressure, cerebral edema, and may even have fatal consequences such as a stroke. Despite C... (Source: SafetyLit)
Source: SafetyLit - September 3, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Stronger Antiplatelet Better for VTE Prophylaxis After Joint Replacement
(MedPage Today) -- Enoxaparin bested aspirin for preventing symptomatic venous thromboembolism (VTE) after total hip or total knee arthroplasty when used without initial anticoagulation in the CRISTAL randomized trial.
These events occurred within... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 23, 2022 Category: Cardiology Source Type: news
Blood Biomarker Linked to Incident VTE in COVID-19 Patients
MONDAY, Aug. 22, 2022 -- Higher levels of soluble urokinase plasminogen activator receptor (suPAR) are associated with incident venous thromboembolism (VTE) among patients hospitalized for COVID-19, regardless of D-dimer levels, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 22, 2022 Category: Pharmaceuticals Source Type: news
VTE Risk Substantially Lower in Breakthrough COVID Cases
(MedPage Today) -- While mild COVID-19 increases venous thromboembolism (VTE) risk, those events are much less likely for vaccinated than unvaccinated patients, a large population-based study showed.
COVID-19 overall raised 30-day risk of deep... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 19, 2022 Category: Cardiology Source Type: news
Updates on Treatment/Prevention of VTE in Cancer Patients Updates on Treatment/Prevention of VTE in Cancer Patients
Updated clinical practice guidelines for the treatment and prevention of venous thromboembolism (VTE) for patients with cancer now include a section on patients who also have COVID-19.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Chrono-pharmacology-based Antiplatelet Therapy for Acute MI Chrono-pharmacology-based Antiplatelet Therapy for Acute MI
A new study uncovered a circadian rhythm in nuclear receptor gene expression in platelets, revealing the importance of circadian rhythmicity in platelet activation and thrombus formation.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 26, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
SVT as a Possible Consequence of ChAdOx1 nCoV-19 Vaccine SVT as a Possible Consequence of ChAdOx1 nCoV-19 Vaccine
This report suggests that superficial venous thrombosis may be an addition to the list of adverse events associated with ChAdOx1 nCoV-19 (Covishield) vaccine.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 14, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mildhaemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1]New data also reinforceHemlibra ’sfavourable safety profile, with no new safety signals observed [1]There is limited information and treatment guidance on moderate and mildhaemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes [2]Hemlibra is approved to treat people of all ages withhaemophilia A with factor VIII inhibitors in more than 110 countries and for people of all ages without factor VIII in...
Source: Roche Media News - July 11, 2022 Category: Pharmaceuticals Source Type: news
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Abelacimab is a dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity
Earlier this year abelacimab became the first-ever Factor XI inhibitor to begin enrolling patients in a Phase 3 trial ... Biopharmaceuticals, FDA Anthos Therapeutics, abelacimab, Factor XI inhibitor, thrombosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 11, 2022 Category: Pharmaceuticals Source Type: news
New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile of Roche ’s Hemlibra in people with moderate or mild haemophilia A
Hemlibra continues to demonstrate clinically meaningful bleed control, with 66.7% of participants with moderate or mildhaemophilia A experiencing zero treated bleeds at 55.6 weeks median follow-up [1]New data also reinforceHemlibra ’sfavourable safety profile, with no new safety signals observed [1]There is limited information and treatment guidance on moderate and mildhaemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes [2]Hemlibra is approved to treat people of all ages withhaemophilia A with factor VIII inhibitors in more than 110 countries and for people of all ages without factor VIII in...
Source: Roche Investor Update - July 11, 2022 Category: Pharmaceuticals Source Type: news
Blood clots: The nation's favourite drink could make your blood sticky – increasing risk
A BLOOD clot in the vein, usually in the leg, is known as deep vein thrombosis - and it can be extremely dangerous, life-threatening even. Could sipping on the nation's favourite drink be increasing your risk? (Source: Daily Express - Health)
Source: Daily Express - Health - July 9, 2022 Category: Consumer Health News Source Type: news
Advances in Thrombosis and Hemostasis From EHA 2022 Advances in Thrombosis and Hemostasis From EHA 2022
Thrombosis and hemostasis highlights from EHA 2022 include fracture risk, treatment tapering, a novel drug in ITP, and management of bleeding risk in cancer, as discussed by Dr Benjamin Brenner.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 7, 2022 Category: Allergy & Immunology Tags: Internal Medicine ReCAP Source Type: news
Blood clots: Two sports linked to a higher risk of deep vein thrombosis ‘in the arms’
BLOOD clots can cause undesirable symptoms, but they tend not to be dangerous unless they break loose and travel to any of the vital organs. Several types of exercise have been linked to a greater risk of blood clotting events. (Source: Daily Express - Health)
Source: Daily Express - Health - July 5, 2022 Category: Consumer Health News Source Type: news
Blood clots: How do you sleep? One position may increase the risk of deep vein thrombosis
THE MOST pressing concern with blood clots is the risk that they'll travel to the lung, which kills hundreds of thousands of people each year. The condition is widely understood as the result of sedentary behaviour. Some sleep positions, however, may also increase the risk of the complication. (Source: Daily Express - Health)
Source: Daily Express - Health - July 3, 2022 Category: Consumer Health News Source Type: news
Study Confirms Increased CVT With AstraZeneca COVID Vaccine Study Confirms Increased CVT With AstraZeneca COVID Vaccine
Rates of cerebral venous thrombosis and thrombocytopenia were higher in patients who received the AstraZeneca COVID-19 vaccine in three Nordic countries.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 1, 2022 Category: Cardiology Tags: Cardiology News Source Type: news